...
首页> 外文期刊>Nutrition & Diabetes >Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulinOpen
【24h】

Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulinOpen

机译:Subetta可单独和在存在胰岛素的情况下增加胰岛素受体β亚基的磷酸化

获取原文

摘要

It has been previously shown that Subetta (a drug containing released-active forms of antibodies to the insulin receptor β-subunit and antibodies to endothelial nitric oxide synthase) stimulated insulin-induced adiponectin production by mature human adipocytes in the absence of insulin. Therefore, it was assumed that Subetta could activate the insulin receptor. To confirm this hypothesis, the capacity of Subetta to activate the insulin receptor in mature human adipocytes in the absence or presence of the insulin was investigated. Cells were incubated either with Subetta or with vehicle, or with basal medium for 3 days. Then, adipocytes were treated with water or insulin (100?nm) for 15?min. Following treatment, lysates were prepared and phosphorylation of insulin receptor β-subunits was analyzed by western blot analysis. It was shown that Subetta significantly increased (P<0.001) the ‘phosphorylated-insulin receptor β-subunit/total insulin receptor β-subunit’ ratios in both the presence and the absence of insulin. These results support previously published data and indicate that Subetta could activate the insulin receptor through the effect on its β-subunits, whose conformational state is essential for insulin receptor activation. This action might serve as one of the primary mechanisms of the drug’s antidiabetic effect.
机译:先前已经表明,Subetta(一种包含释放的活性形式的针对胰岛素受体β亚基的抗体和针对内皮型一氧化氮合酶的抗体的药物)可在不存在胰岛素的情况下,通过成熟的人脂肪细胞刺激胰岛素诱导的脂联素生成。因此,假设Subetta可以激活胰岛素受体。为了证实这一假设,研究了在不存在或存在胰岛素的情况下,Subetta激活成熟人脂肪细胞中胰岛素受体的能力。将细胞与Subetta或与溶媒或与基础培养基一起温育3天。然后,将脂肪细胞用水或胰岛素(100?nm)处理15分钟。处理后,制备裂解物,并通过蛋白质印迹分析来分析胰岛素受体β亚基的磷酸化。结果表明,无论有无胰岛素存在,Subetta均可显着提高(P <0.001)“磷酸化胰岛素受体β亚基/总胰岛素受体β亚基”的比率。这些结果支持以前发表的数据,并表明Subetta可以通过对其β亚基的作用来激活胰岛素受体,其β构象状态对于胰岛素受体的激活至关重要。这种作用可能是该药抗糖尿病作用的主要机制之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号